Literature DB >> 27553377

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

Jason Grebely1, Gregory J Dore1, Stefan Zeuzem2, Richard J Aspinall3, Raymond Fox4, Lingling Han5, John McNally5, Anu Osinusi5, Diana M Brainard5, G Mani Subramanian5, Macky Natha5, Graham R Foster6, Alessandra Mangia7, Mark Sulkowski8, Jordan J Feld9.   

Abstract

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  HCV; OST; PWID; sofosbuvir; velpatasvir

Mesh：

Substances：

Year:  2016        PMID： 27553377      PMCID： PMC5106608          DOI： 10.1093/cid/ciw579

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.

Authors:  Jacob Lalezari; J Greg Sullivan; Peter Varunok; Edward Galen; Kris V Kowdley; Vinod Rustgi; Humberto Aguilar; Franco Felizarta; Barbara McGovern; Martin King; Akshanth R Polepally; Daniel E Cohen
Journal:  J Hepatol       Date:  2015-04-01       Impact factor: 25.083

2.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

Review 3.  Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Authors: 
Journal:  Hepatology       Date:  2015-08-04       Impact factor: 17.425

Review 4.  Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

Authors:  Esther J Aspinall; Stephen Corson; Joseph S Doyle; Jason Grebely; Sharon J Hutchinson; Gregory J Dore; David J Goldberg; Margaret E Hellard
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Authors:  Gregory J Dore; Frederick Altice; Alain H Litwin; Olav Dalgard; Edward J Gane; Oren Shibolet; Anne Luetkemeyer; Ronald Nahass; Cheng-Yuan Peng; Brian Conway; Jason Grebely; Anita Y M Howe; Isaias N Gendrano; Erluo Chen; Hsueh-Cheng Huang; Frank J Dutko; David C Nickle; Bach-Yen Nguyen; Janice Wahl; Eliav Barr; Michael N Robertson; Heather L Platt
Journal:  Ann Intern Med       Date:  2016-08-09       Impact factor: 25.391

6.  Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

Authors:  Jason Grebely; Stefan Mauss; Ashley Brown; Jean-Pierre Bronowicki; Massimo Puoti; David Wyles; Macky Natha; Yanni Zhu; Junming Yang; Bruce Kreter; Diana M Brainard; Chohee Yun; Val Carr; Gregory J Dore
Journal:  Clin Infect Dis       Date:  2016-08-23       Impact factor: 9.079

Review 7.  Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.

Authors:  Rositsa B Dimova; Marija Zeremski; Ira M Jacobson; Holly Hagan; Don C Des Jarlais; Andrew H Talal
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

Review 8.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.

Authors:  Bryony Simmons; Jawaad Saleem; Andrew Hill; Richard D Riley; Graham S Cooke
Journal:  Clin Infect Dis       Date:  2016-01-19       Impact factor: 9.079

9.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.

Authors:  Graham R Foster; Nezam Afdhal; Stuart K Roberts; Norbert Bräu; Edward J Gane; Stephen Pianko; Eric Lawitz; Alex Thompson; Mitchell L Shiffman; Curtis Cooper; William J Towner; Brian Conway; Peter Ruane; Marc Bourlière; Tarik Asselah; Thomas Berg; Stefan Zeuzem; William Rosenberg; Kosh Agarwal; Catherine A M Stedman; Hongmei Mo; Hadas Dvory-Sobol; Lingling Han; Jing Wang; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Francesco Mazzotta; Tram T Tran; Stuart C Gordon; Keyur Patel; Nancy Reau; Alessandra Mangia; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-11-17       Impact factor: 91.245

10.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245
View more
  31 in total

Review 1.  Challenges Facing a Rural Opioid Epidemic: Treatment and Prevention of HIV and Hepatitis C.

Authors:  Asher J Schranz; Jessica Barrett; Christopher B Hurt; Carlos Malvestutto; William C Miller
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

Review 2.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

3.  Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.

Authors:  Alyona Mazhnaya; Anna Meteliuk; Tetiana Barnard; Alexei Zelenev; Sergii Filippovych; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2017-08-12

Review 4.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

5.  Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.

Authors:  Jason Grebely; Tracy Swan; Matthew Hickman; Julie Bruneau; Philip Bruggmann; Olav Dalgard; Alain Litwin; Markus Backmund; Gregory J Dore
Journal:  J Hepatol       Date:  2017-02-03       Impact factor: 25.083

6.  Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?

Authors:  Dimitra Panagiotoglou; Emanuel Krebs; Jeong Eun Min; Michelle Olding; Keith Ahamad; Lianping Ti; Julio S G Montaner; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2017-06-01

Review 7.  HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.

Authors:  Marianne Martinello; Behzad Hajarizadeh; Jason Grebely; Gregory J Dore; Gail V Matthews
Journal:  Curr HIV/AIDS Rep       Date:  2017-06       Impact factor: 5.071

Review 8.  Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.

Authors:  Brianna L Norton; Matthew J Akiyama; Philippe J Zamor; Alain H Litwin
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

9.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03

Review 10.  Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination.

Authors:  Fátima Higuera-de la Tijera; Alfredo Servín-Caamaño; Luis Servín-Abad
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.